Inhaled Insulin

4173

Inhaled insulin offers the same blood glucose control as conventional subcutaneous insulin for people with type 2 diabetes that was previously managed with at least two insulin injections a day. It’s also as effective and is well tolerated and safe.

In a six-month multicenter study, type 2s were randomized to either inhaled Exubera insulin before meals and a single injection of long-acting Ultralente insulin daily or at least two injections of mixed Regular and NPH insulin daily.

A1C decreased similarly in the Exubera and subcutaneous insulin groups. More patients in the Exubera group achieved an A1C of less than 7%.

Hypoglycemia was slightly lower in the inhaled group. There was little to no difference in severe adverse events or pulmonary function. Other adverse events, with the exception of cough in the inhaled insulin group, were similar.

Diabetes Care, October 2004

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.